Managed care in benign gynecology.
The invasion of managed care into the American health system has led to drastic and potentially salutary changes in both the locus and delivery of care. With a focus on cost-effectiveness and decisions based on outcomes analysis, the rationale of many traditional management options has been called into question. A discussion of how the implementation of this new evidence-based, cost-centered gold standard has affected the management of four benign gynecologic processes is the purpose of this update.
Montz
F J
FJ
Gynecologic Oncology Service, Jonsson Comprehensive Cancer Center, University of California Los Angeles Center for Health Sciences 90095, USA.
D003362:Cost-Benefit Analysis; D019317:Evidence-Based Medicine; D005260:Female; D005831:Genital Diseases, Female / Q000175:diagnosis* / Q000628:therapy*; D006176:Gynecology / Q000458:organization & administration*; D006801:Humans; D015907:Hysteroscopy; D010535:Laparoscopy; D008329:Managed Care Programs / Q000458:organization & administration*; D017063:Outcome Assessment, Health Care